Israel says Pfizer vaccine effectiveness against Covid-19 down to 64%

The effectiveness of the Pfizer vaccine against Covid-19 has dropped to 64 per cent in Israel, the country's Ministry of Health said.

Topics
Pfizer | Coronavirus Vaccine | israel

IANS  |  Tel Aviv 

Pfizer Vaccine, Coronavirus vaccine
Photo: Shutterstock

The effectiveness of the vaccine against Covid-19 has dropped to 64 per cent in Israel, the country's Ministry of Health said.

The new figure refers to the period between June 6 and July 3, and it is significantly lower than the effectiveness rate of 94.3 percent in protection against infection, measured between May 2 and June 5, Xinhua news agency quoted the Ministry as saying on Monday.

It noted that the decline was observed along with the spread of the Delta Covid-19 variant in

However, the effectiveness of the vaccine in preventing hospitalisations and severe coronavirus disease is currently estimated at 93 per cent in

The Ministry currently promotes the administration of a third vaccine dose to those who have suffered a functional decline in the immune system, but there is currently no decision to launch a third dose campaign for the entire population.

Since the start of the vaccination campaign in on December 20, 2020, over 5.65 million people, or 60.6 per cent of the population, have received the first dose of the vaccine, while 5.18 million have received the second dose.

--IANS

ksk/

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Pfizer
First Published: Tue, July 06 2021. 09:47 IST
RECOMMENDED FOR YOU